Clinical Trial Update: Aflibercept in Treating Patients With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 study of aflibercept in patients with various myelodysplastic syndromes was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Chronic Myeloid Leukemia Bcr-abl1 Negative
• De Novo Myelodysplastic Syndromes
• Myelodysplastic Myeloproliferative Neoplasm Unclassifiable
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia
• Previously Treated Myelodysplastic Syndromes

Drugs mentioned

• Zaltrap (ramucirumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2015-01-08